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Postprandial hyperemia is associated with a signiﬁcant increase in portal pressure in cirrho-
sis,whichmaycontributetoprogressivedilationandruptureofgastroesophagealvarices.In
cirrhosis, an insufﬁcient hepatic production of nitric oxide (NO) may impair the expected
hepatic vasodilatory response to increased blood ﬂow, further exaggerating the postprandial
increase in portal pressure. This study was aimed at investigating whether low doses of an
oral NO donor might counteract the postprandial peak in portal pressure. Twenty-three
portal hypertensive cirrhotics, 8 of them under propranolol therapy, were randomized to
receive orally 5-isosorbide mononitrate (ISMN; 10 mg; n  11) or placebo (n  12) and a
standard liquid meal 15 minutes later. Hepatic venous pressure gradient (HVPG), mean
arterialpressure(MAP),andhepaticbloodﬂow(HBF)weremeasuredatbaselineand15,30,
and 45 minutes after a meal. ISMN signiﬁcantly attenuated the postprandial increase in
portal pressure as compared with placebo (peak HVPG increase: 2.4  1.4 mm Hg vs. 5.2 
2.1 mm Hg, P  .002). Percentual increases in HBF were similar in both groups. MAP
decreased slightly in ISMN group (7.5%  .5%; P < .01 vs. baseline). These effects were
also observed in patients on chronic propranolol therapy. In conclusion, hepatic NO sup-
plementation by low doses of ISMN effectively reduces the postprandial increase of portal
pressure in cirrhosis, with only a mild effect on arterial pressure. The same was observed in
patients receiving propranolol. Our results suggest that therapeutic strategies based on
selective hepatic NO delivery may improve the treatment of portal hypertension.
(HEPATOLOGY 2003;37:378-384.)
S
everal studies have shown that, in normal subjects,
food intake induces marked changes in splanchnic
hemodynamics.1-5 The main ﬁnding is a postpran-
dial increase in splanchnic blood ﬂow, caused by splanch-
nic arteriolar vasodilatation occurring in the submucosal
and mucosal layers of the small intestine. This postpran-
dial splanchnic vasodilatation and hyperemia occur ow-
ing to the interaction of intrinsic mechanisms (such as
changes in arteriolar transmural pressure and/or increase
in vasodilator tissue metabolites) and extrinsic mecha-
nisms (action of autonomic nervous system) and to the
effect of gastrointestinal hormones.1-4,6,7
On the other hand, in cirrhotic patients, the postpran-
dial hyperemia determines a signiﬁcant increase of portal
and collateral blood ﬂow, which results in an increased
hepatic venous pressure gradient (HVPG).3,7-15 This is
observed rapidly, the maximum changes in splanchnic
hemodynamics being observed at 30 minutes after the
meal, returning to basal levels at 120 minutes.3,8,9,11-14
Thesedatasuggestthat,incirrhoticpatients,therepeated
increase in portal venous pressure because of food intake
may contribute to the progressive portal-systemic collat-
eral dilation and to the development and dilation of the
varices that eventually lead to variceal bleeding.
Propranolol administration has been reported to re-
duce the postprandial peak in portal pressure,10 but sub-
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378sequent studies demonstrated that postprandial increases
in portal pressure15 and blood ﬂow5,16 are not blunted—
the only difference being that the baseline value is lower
than before taking -blockers—because the magnitude
of the postprandial peak in portal pressure was essentially
unaffected.15
Several recent studies have shown that the cirrhotic
liver exhibits endothelial dysfunction that results in a de-
fective or absent vasodilatory response to acetylcholine
and in an insufﬁcient nitric oxide (NO) production by
endothelial nitric oxide synthase in the intrahepatic vas-
cular bed.17-19 Such a deﬁcient NO production increases
the hepatic vascular tone and may decrease the intrahe-
patic vasodilatory adaptive response to sudden increases
in blood ﬂow. Thus, the physiologic postprandial hyper-
emia is likely to result in a higher than anticipated and
brisk increase in portal pressure. These observations sug-
gest that, if NO can be provided to the hepatic circula-
tion, the postprandial increase of portal pressure could be
prevented or signiﬁcantly attenuated.
Isosorbide-5-mononitrate (ISMN) is an NO donor
drug completely absorbed after oral administration,
whichcausesdose-related,signiﬁcantreductionsofportal
pressure in patients with cirrhosis.20-23 At relatively low
doses (20 mg), ISMN has been shown to decrease portal
pressure without reducing hepatic blood ﬂow (HBF),23
suggesting that it decreases hepatic resistance by intrahe-
patic NO supplementation.
The primary aim of this study was to investigate
whether an even lower dose (10 mg) of ISMN, which by
itself does not modify baseline HVPG, could prevent the
postprandial increase of portal pressure in patients with
cirrhosisandportalhypertension.Furthermore,weaimed
to study whether ISMN effects on postprandial hemody-
namicswerealsopresentinpatientsundercontinuedpro-
pranolol therapy.
Patients and Methods
Patients. The study was performed in 23 cirrhotic
patients (17 men and 6 women) referred to our unit for
hemodynamic evaluation of portal hypertension. The
study was performed according to the principles of the
Declaration of Helsinki, (revision of Edinburgh 2000)
and was approved by the Human Research Committee of
theHospitalClinicinMay2000.Thenatureofthestudy
was explained to the patients, and written informed con-
sent was obtained in each case.
All patients had cirrhosis diagnosed by clinical, bio-
chemical, ultrasonographic, and/or histologic criteria.
Meanageofthepatientswas5411years.Meanweight
was 78.7  11.8 kg. Eleven patients belonged to Child-
Pugh class A, 11 to class B, and 1 to class C. The mean
Child-Pugh score was 6.9  1.8 points (range 5-11). The
etiology of cirrhosis was hepatitis C virus related in 14
patients, alcoholic in 6, alcoholic and hepatitis C virus in
1,autoimmunecirrhosisin1,andunknownin1.Twenty
patients had esophageal varices, 12 (that were large in all
cases) had previously bleed. Four were under propranolol
treatment and 8 treated with endoscopic therapy. Among
those with no previous bleeding, 4 had large varices and
were treated with propranolol. Seven patients had ascites,
4ofthemweretreatedwithspironolactoneand3withthe
combination of furosemide and spironolactone.
Patients were considered eligible for the study if they
were found to have an HVPG 12 mm Hg during the
hemodynamic study. Exclusion criteria were the follow-
ing:arterialhypotension(deﬁnedbyasystolicbloodpres-
sure of 90 mm Hg), hypersensitivity to isosorbide-5-
mononitrate, pregnancy, hepatic failure as deﬁned as
prothrombinrate40%andbilirubin5mg/dL,portal
vein thrombosis, diffuse or multinodular hepatocellular
carcinoma, and previous surgical or transjugular intrahe-
patic portosystemic shunt.
Sample Size Calculation. We calculated that, to de-
tect a 50% difference in the postprandial increase in
HVPG between placebo and ISMN groups with a
2-tailed test,  risk of 5%, and  risk of 20%, at least 11
patients should be included in each treatment arm. We
assumedastandarddeviationof12frompreviousunpub-
lished data from our laboratory.
Methods. After an overnight fast, the patients were
transferred to the Hepatic Hemodynamic Laboratory.
Under local anesthesia, an 8F venous catheter introducer
(Axcess; Maxxim Medical, Athens, TX) was placed in the
right femoral vein or in the right jugular vein under ultra-
sonographicguidanceusingtheSeldingertechnique.Un-
der ﬂuoroscopic control, a 7F balloon-tipped catheter
(Medi-Tech; Boston Scientiﬁc Cork Ltd., Cork, Ireland)
was advanced into the main right hepatic vein to measure
wedged hepatic venous pressure (WHVP) and free he-
patic venous pressure. All measurements were performed
in triplicate, and permanent tracings were recorded.
Preceded by a priming dose (5 mg), a solution of indo-
cyanine green (ICG; Pulsion Medical Systems, Munich,
Germany) was infused intravenously at a constant rate of
0.2 mg/min. After an equilibration period of at least 40
minutes, 4 separate sets of simultaneous samples of pe-
ripheral and hepatic venous blood were obtained for the
measurement of HBF as previously described.23 Mean
arterialpressurewasmeasurednoninvasivelyevery5min-
utes by an automatic electronic sphygmomanometer
(MarquetteElectronics,NY).Heartratewasderivedfrom
continuous electrocardiogram monitoring.
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ments, patients were randomized to receive in double-
blindconditionseitherISMN(10mg,n11)orplacebo
(10 mg lactose, n  12) orally. This ISMN dose was
chosentominimizethepossibilityofsplanchnicvasocon-
striction, following the results obtained in a preliminary
dose-ﬁnding study in which this dose of ISMN (10 mg)
caused a mild decrease in mean arterial pressure (MAP)
(5%  6%), without signiﬁcant changes in HVPG
(2%  5%) (n  4). Fifteen minutes after drug inges-
tion, a liquid meal (400 mL) containing 25 g of proteins,
80.8gofcarbohydrates,and19.68goflipidsforatotalof
600 kcal (Ensure Plus; Abbott Laboratories B.V., Zwolle,
The Netherlands) was given to each patient and was in-
gestedwithinapproximately5minutes.Theonsetofmeal
ingestion was considered as time zero. Postprandial he-
modynamic measurements were repeated at minute 15,
30,and45.At15minutesand30minutes,3separatesets
of simultaneous samples of peripheral and hepatic venous
blood were taken for HBF measurement.
Statistics. Statistics were performed using SPSS 10.0
statisticalpackage(SPSSInc.,Chicago,IL).Allresultsare
expressedasmeanSDvalues.Comparisonswithineach
groupwereperformedwithStudent’sttestforpaireddata
and comparisons between groups with Student’s t test for
unpaired data. ANOVA test for repeated measurements
was used when appropriate. Preplanned contrast analysis
was performed to compare each time point against base-
line. A P value of  .05 was considered signiﬁcant.
Results
Baseline clinical and hemodynamic data are shown in
Table1.Allstudiedpatientshadclinicallysigniﬁcantpor-
tal hypertension (median HVPG 15 mm Hg, range 12-
27.5 mm Hg). There were no signiﬁcant differences
between patients randomized to ISMN or placebo in any
parameter at baseline.
The placebo group (n  12) showed a marked and
statistically signiﬁcant postprandial increase of HVPG
(ANOVA, P  .0001); in agreement with previous ob-
servations, it was mostly due to the increase in WHVP,
without signiﬁcant changes in free hepatic venous pres-
sure(Table2).TheincreaseinHVPGwasalreadypresent
15 minutes after the meal (26%  17.8%; P  .0001 vs.
baseline); it was maximum at 30 minutes (29.1% 
14.9%; P  .0001 vs. baseline) and persisted at 45 min-
utes (21.8%  20.8%; P  .001 vs. baseline). The peak
changeofHVPGwasof5.22.1mmHg.Inthisgroup,
the HVPG increase was associated with an increase in
HBF that averaged 23.1%  28.4% at 15 minutes (P 
.03 vs. baseline) and 18.2%  24.8% at 30 minutes (P 
.04 vs. baseline). Ingestion of the test meal was not fol-
lowed by signiﬁcant changes in MAP and heart rate in
patients receiving placebo (Table 2).
In patients receiving ISMN (n  11), HVPG also
increasedsigniﬁcantlyafterthemeal(ANOVA,P.01).
However, when compared with patients receiving pla-
cebo, the postprandial rise in portal pressure was mark-
edly and signiﬁcantly reduced at every time point: 12.7%
 7.7% vs. 26.0%  17.8% at 15 minutes (P  .04),
10.4%  9% vs. 29.1%  14.9% at 30 minutes (P 
.01), and 5.2%  8.3% vs. 21.8%  20.8% at 45 min-
utes (P  .03) (Fig. 1A).
A similar blunting of the postprandial increase in
HVPG was observed when expressing the results as abso-
Table 1. Clinical and Hemodynamic Data of the Patients
Studied at Baseline
Placebo
(n  12)
ISMN
(n  11)
Sex (M/F) 10/2 7/4
Age (yr) 58  11 50  11
Child-Pugh (score) 6.7  2.2 7.3  1.3
Varices (%) 92 82
Ascites (%) 17 46
Propranolol Rx (n) 4 4
HVPG (mm Hg) 16.0  2.8 16.9  5.2
MAP (mm Hg) 86  16 82  10
HBF (mL/min) 792  172 977  492
HR (bpm) 72  14 76  14
Table 2. Postprandial Change in Hepatic Venous Pressures After Placebo Versus ISMN
Placebo (n  12) ISMN (n  11)
Baseline 15 Min 30 Min 45 Min Baseline 15 Min 30 Min 45 Min
WHVP (mm Hg) 23.2  3.3 28.6  4.5* 28.8  4.7* 27.7  5.3* 26.5  4.8 29.4  5.7* 28.9  6.1* 27.1  5.0*
FHVP (mm Hg) 7.2  2.0 8.4  2.8 8.2  2.6 7.9  2.8 9.6  2.8 10.4  2.8 10.3  3.0 10.4  3.2
HVPG (mm Hg) 16.0  2.8 20.2  4.4* 20.6  3.8* 19.8  4.6* 16.9  5.2 19.0  6.0* 18.6  6.0* 16.7  4.2
HBF (mL/min) 792  172 993  370* 963  376* — 977  492 1,199  481* 1,018  263 —
MAP (mm Hg) 86  16 89  17 88  16 88  16 82  10 76  9* 75  8* 76  9*
HR (bpm) 72  14 74  15 75  14 76  16 76  14 79  14 78  16 79  16
*P  .05 vs. baseline.
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was signiﬁcantly lower in these patients (2.4  1.4 mm
Hg)thaninthosereceivingplacebo(5.22.1mmHg;P
 .002).
The percentage increase in HBF after food intake in
patients receiving ISMN was similar to that observed in
the placebo group. However, in ISMN group, HBF at 30
minutes returned to values that were not different from
baseline and, in the placebo group, remained increased at
all time points (Fig. 2, Table 2).
MAP decreased signiﬁcantly by a value of 6.5% 
8.2% at minute 15, 7.5%  6.5% at minute 30, and
6.2%  8.7% at minute 45 in the ISMN group (maxi-
mumobserveddecrease:65mmHgor7.5%6.5%)
(Fig. 3, Table 2). Heart rate remained unchanged.
Patients who were under chronic propranolol therapy
had similar baseline HVPG as patients who were not
(16.6  2.7 mm Hg vs. 16.3  4.8 mm Hg, respectively;
NS). These patients also exhibited a signiﬁcant and
marked rise in HVPG in the placebo group (n  4; peak
increase5.11.3mmHg)thatwassigniﬁcantlyblunted
inISMN-treatedpatients(n4;peakincrease2.61.0
mm Hg; P  .02 vs. placebo) (Fig. 4). At each measure-
ment point, there were no differences in HBF in ISMN-
treated patients as compared with placebo. However,
although MAP did not change after placebo, it decreased
signiﬁcantly in the ISMN group (8  5m mH ga t3 0
minutes). There were no adverse reactions during or as a
consequence of the study.
Discussion
Portal hypertension in cirrhosis results from the inter-
action of an increased resistance to portal blood ﬂow
through the cirrhotic liver and an increased portal venous
inﬂow. Most attempts to correct the portal hypertensive
syndrome have been based on the pharmacologic reduc-
Fig. 1. Postprandial changes of HVPG in patients receiving ISMN or
placebo. Data are shown as percentage change from baseline (mean 
SEM) (A) and as absolute changes (B).
Fig. 2. Postprandial changes of HBF in patients receiving ISMN or
placebo. Data are shown as percentage change from baseline (mean 
SEM).
Fig. 3. Postprandial changes of MAP in ISMN vs. placebo (mean 
SEM).
Fig. 4. Postprandial changes of HVPG in ISMN vs. placebo, in patients
on long-term propranolol (mean  SEM).
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tive -blockers or other splanchnic vasoconstrictors such
as terlipressin, somatostatin, or somatostatin deriva-
tives.24 However, recent investigations have shown that,
in cirrhosis, the increased hepatic resistance is not only a
mechanical consequence of the distortion of the intrahe-
patic vascular architecture because of ﬁbrosis, scarring,
and nodule formation but that there is also a dynamic
component because of the active contraction of different
cells with contractile activity, such as vascular smooth
muscle cells, activated hepatic stellate cells around the
sinusoids, and myoﬁbroblasts in the ﬁbrous septa.25-27 In
experimental models, this dynamic component is exag-
gerated by a deﬁcit in the production of the endogenous
vasodilator NO in the intrahepatic circulation, which ap-
pearstobeduetoadecreasedactivityofendothelialnitric
oxide synthase.17,19,28,29 Such an insufﬁcient hepatic pro-
duction of NO provides a rationale for the use of nitro-
vasodilators in the treatment of portal hypertension
because it is conceivable that supplementation of NO in
the intrahepatic circulation will reduce the hepatic resis-
tanceand,hence,portalpressure.Indeed,previousstudies
from our laboratory have shown that the administration
ofISMNcausesdose-relatedreductionsofportalpressure
in cirrhosis.20,23 At relatively low doses (20 mg) or during
continued administration, the fall in portal pressure was
almost entirely due to a decrease in hepatic resistance
because there was no decrease in HBF. However, ISMN
does not allow a selective delivery of NO at the intrahe-
patic circulation, which means that this agent causes sys-
temic hypotension, undesirable in patients with cirrhosis.
However, this and previous studies from our laboratory
have shown that this effect is also dose related and mild at
relatively low doses.23 Although it has been proposed that
other agents such as NCX-1000, a NO-releasing deriva-
tive of ursodeoxycholic acid, would allow such a targeted
hepatic delivery of NO,30 this has not been studied in
portal hypertensive subjects. Another possibility is to
overexpress the nitric oxide synthase gene in the liver by
the use of gene therapy,31,32 but this is far from being
clinically applicable.
In the present study, we hypothesized that, given the
fact that ISMN is totally absorbed after its oral adminis-
tration, the administration of a very low dose of ISMN
will allow it to reach a high enough hepatic concentration
as to dilate effectively the intrahepatic circulation while
limiting its unwanted systemic vasodilatory effect. We
further proposed that this hepatic NO supplementation
could abrogate the postprandial increase in portal pres-
sure. Finally, we also aimed at examining whether this
effect may also be observed in patients under continued
propranolol therapy.
Theresultsofourstudyconﬁrmthattheintakeofatest
meal causes a rapid and pronounced increase in portal
pressure both in patients under no treatment or in those
taking propranolol, thus conﬁrming previous studies.15
More importantly, the study demonstrates that the ad-
ministration of a low dose of ISMN (10 mg), but not of
placebo, largely prevented the postprandial increase in
portal pressure. Again, this effect was also observed in
patients under continued propranolol therapy. It is of
note that ISMN not only ameliorated both postprandial
HVPG peak and hyperemia but also shortened them,
whereas, in the placebo group, HBF values at 30 minutes
and HVPG at 45 minutes were still higher than baseline
values; in the ISMN group, they were not any more. This
also raises the possibility of some degree of splanchnic
vasoconstriction because of the persistent, although mild,
signiﬁcant decrease in mean arterial pressure, as has been
shown in experimental models.33 These ﬁndings may
have relevant implications both in the understanding of
the pathophysiology of the increased intrahepatic resis-
tanceincirrhosisandinthetreatmentofportalhyperten-
sion.
From a conceptual point of view, ourﬁndings strongly
support the view that, as shown in experimental mod-
els,17,19,28,29 patients with cirrhosis may have an insufﬁ-
cient production of NO in the hepatic circulation (which
has been called intrahepatic “endothelial dysfunction”).17
Such decreased availability of NO in the hepatic circula-
tion may play a key role in increasing hepatic resistance
and aggravating the postprandial increase in portal pres-
sure.Therepeatedpostprandialincreaseinportalpressure
may be an important determinant of the progressive dila-
tion of the varices.
From a practical standpoint, our ﬁndings provide fur-
thersupportfortheuseoflowdosesofISMNinconjunc-
tion with propranolol therapy. We have previously
demonstrated that the combined administration of
ISMN and propranolol has a synergistic effect decreasing
portal pressure without causing adverse renal effects.34
Although there is no direct evidence to conclude that this
combination fares better than propranolol alone in pre-
venting variceal rebleeding,35 2 large randomized con-
trolled trials have supported the view that it may be
superior to endoscopic injection sclerotherapy or to band
ligation.36,37 An issue that remains unanswered in this
study is whether tolerance develops for this particular ef-
fectofISMN,butprevioushemodynamicstudiesshowed
that systemic hypotension and the portal pressure-lower-
ing effect of ISMN are maintained after long-term, con-
tinuous administration in patients with cirrhosis.20,38,39
The above considerations should not be taken as an
argument against the search for other agents for the treat-
382 BELLIS ET AL. HEPATOLOGY, February 2003mentofportalhypertension.Onthecontrary,theneedof
further investigation is emphasized by our ﬁndings be-
cause the response to therapy may be improved signiﬁ-
cantly by associating agents acting through different
mechanisms,andthatmaycorrectinpart,inthatway,the
multiple abnormalities leading to portal hypertension. In
summary, our results suggest that therapeutic strategies
based on selective hepatic NO delivery may improve the
treatment of portal hypertension.
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